asking for myself but also just genuinely curious about the pharmacology here bc i can’t find a clear answer anywhere. context: i’m 42, 8 mos pp, been on tirz since december. went 5mg → 7.5 → now 10mg. but when i titrated i always happened to run out of the lower dose naturally before the new shipment came. so i never had leftover pens sitting there. the specific scenario i keep seeing (and hearing from a few people in my due date group who are also on it): food noise comes back hard around week 8-10 of a given dose, person still has 2-3 injections left, now they’re not sure whether to a) finish those out and THEN start the new dose
b) just open the new box and start it now
c) dose the remaining lower ones faster to get through them quicker the question i can’t find answered is whether there’s an actual pharmacological reason to finish the lower pens vs just switching. like does the residual tirz from a 5mg dose interfere with titrating to 7.5? or are we just being economical about not wasting medication? because ‘appetite wore off at this dose’ sounds a lot like ‘you’ve hit your ceiling here’ to me, not ‘the drug stopped working, take more of the same thing.’ which would mean finishing those pens is just prolonging the plateau, not helping it. or am i wrong about that. genuine question, not rhetorical. what did your prescriber say when you asked?
Your instinct about “ceiling here” vs “the drug stopped working” is the right frame to be pulling on, and no, residual 5mg doesn’t meaningfully interfere with starting 7.5. Tirz has roughly a five-day half-life, so you’re already overlapping with yourself on weekly dosing anyway. Finishing the lower pens is economic, not pharmacological. The part I’d push back on gently: “food noise came back at week 8-10” isn’t one thing. Gastric emptying attenuation can produce that signal independently of receptor adaptation, and they don’t point to the same fix. Worth understanding which mechanism is actually running before assuming more drug is the answer.
the gastric emptying point is genuinely useful framing, i hadn’t thought about it that way. but “worth understanding which mechanism is actually running” isn’t actionable without knowing what the different fixes look like, and you left that part out. if one mechanism points to holding at current dose longer and the other points to titrating regardless, that’s a completely different decision. that’s the hole in the advice, and honestly the thing the original question was circling around the whole time.
The gap you’re pointing at is real, and mechanism without implication is incomplete advice. But here’s where I’d push back on “hold vs. titrate” as the frame that resolves it: the three mechanisms don’t sort cleanly into those two options, and that’s not an accident. Gastric emptying attenuation and behavioral drift specifically are not addressed by titrating. A higher dose doesn’t restore the half-emptying curve, and it doesn’t retrain conditioned eating responses that formed while the drug was quieting food noise. So titrating is the right answer only if receptor adaptation is what’s actually running. If either of the other two mechanisms is primary, you’ve moved to 10mg and the underlying driver is still there, just now at the new dose. The action step that changes is not “hold or titrate” but “is titrating even the right lever for what’s driving this,” which has a different answer for each mechanism. I’d push back on the framing that I left out the action step. What I was trying to preserve was the prior question, the one where the three paths actually diverge. imo Collapsing it to the binary before that question is answered is exactly what leads to dose escalating the wrong mechanism.